163 related articles for article (PubMed ID: 12842538)
1. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.
Brooks KR; To K; Joshi MB; Conlon DH; Herndon JE; D'Amico TA; Harpole DH
Ann Thorac Surg; 2003 Jul; 76(1):187-93; discussion 193. PubMed ID: 12842538
[TBL] [Abstract][Full Text] [Related]
2. Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA/IIIB NSCLC patients.
Morero JL; Poleri C; Martín C; Van Kooten M; Chacón R; Rosenberg M
J Thorac Oncol; 2007 Apr; 2(4):293-8. PubMed ID: 17409800
[TBL] [Abstract][Full Text] [Related]
3. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
[TBL] [Abstract][Full Text] [Related]
5. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
Hirsch FR; Herbst RS; Olsen C; Chansky K; Crowley J; Kelly K; Franklin WA; Bunn PA; Varella-Garcia M; Gandara DR
J Clin Oncol; 2008 Jul; 26(20):3351-7. PubMed ID: 18612151
[TBL] [Abstract][Full Text] [Related]
6. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor.
Manac'h D; Riquet M; Medioni J; Le Pimpec-Barthes F; Dujon A; Danel C
Ann Thorac Surg; 2001 Apr; 71(4):1088-93. PubMed ID: 11308141
[TBL] [Abstract][Full Text] [Related]
7. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
8. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
Cicenas S; Zaliene A; Atkocius V
Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
[TBL] [Abstract][Full Text] [Related]
9. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
[TBL] [Abstract][Full Text] [Related]
10. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
11. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Chiappori AA; Ellis PM; Hamm JT; Bitran JD; Eiseman I; Lovalvo J; Burnett D; Olson S; Lenehan P; Zinner RG
J Thorac Oncol; 2006 Nov; 1(9):1010-9. PubMed ID: 17409987
[TBL] [Abstract][Full Text] [Related]
12. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881.
Wagner H; Lad T; Piantadosi S; Ruckdeschel JC
Chest; 1994 Dec; 106(6 Suppl):348S-354S. PubMed ID: 7988262
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
15. Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
Baldini E; Silvano G; Tibaldi C; Campoccia S; Cionini L; Conte P
Semin Oncol; 2000 Feb; 27(1 Suppl 1):28-32. PubMed ID: 10697041
[TBL] [Abstract][Full Text] [Related]
16. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
[TBL] [Abstract][Full Text] [Related]
17. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
Rice TW; Adelstein DJ; Koka A; Tefft M; Kirby TJ; Van Kirk MA; Taylor ME; Olencki TE; Peereboom D; Budd GT
Ann Thorac Surg; 1995 Sep; 60(3):586-91; discussion 591-2. PubMed ID: 7677484
[TBL] [Abstract][Full Text] [Related]
18. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
[TBL] [Abstract][Full Text] [Related]
19. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
[TBL] [Abstract][Full Text] [Related]
20. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
